What follow‑up plan should be implemented for an 84‑year‑old woman with a surgery‑provoked deep‑vein thrombosis and pulmonary embolism after hip fracture repair (open‑reduction internal fixation), who is now on apixaban (Eliquis) 5 mg twice daily and was on a therapeutic heparin infusion during hospitalization?

Follow-Up Management for Surgery-Provoked DVT/PE After Hip Fracture ORIF

This 84-year-old patient with surgery-provoked VTE should continue apixaban 5 mg twice daily for a minimum of 3 months total duration from the time of diagnosis, with no routine laboratory monitoring required, and should be reassessed at 3 months to determine if anticoagulation can be safely discontinued given the provoked nature of her thrombosis. 1, 2

Anticoagulation Duration and Dosing

• Continue apixaban 5 mg orally twice daily for at least 3 months from the time of VTE diagnosis (not from hospital discharge), as this represents the standard treatment duration for surgery-provoked proximal DVT and PE 1, 2

• Do NOT reduce to the 2.5 mg twice-daily dose during the initial 3-month treatment phase—the lower dose is reserved only for extended secondary prevention beyond 6 months in patients requiring indefinite anticoagulation 2, 3

• Plan to discontinue anticoagulation at 3 months if there are no other ongoing risk factors, as surgery-provoked VTE has a low recurrence risk once the provoking factor has resolved 1, 4

Monitoring Requirements

• No routine laboratory monitoring of anticoagulant effect is needed with apixaban, unlike warfarin which requires INR monitoring 2, 3

• Assess renal function (creatinine clearance) at baseline and whenever the clinical situation changes (e.g., acute illness, dehydration, new medications), as worsening kidney function may necessitate dose adjustment or drug discontinuation 2, 5

• Monitor for signs and symptoms of bleeding at each follow-up visit, including easy bruising, hematuria, melena, hemoptysis, or unexplained anemia 3

• Assess for symptoms of recurrent VTE including new or worsening leg swelling, pain, dyspnea, or chest pain 6

Follow-Up Visit Schedule

• Schedule a follow-up visit at 2–4 weeks post-discharge to assess medication adherence, review bleeding precautions, check renal function, and evaluate for early complications 6

• Schedule a 3-month follow-up visit to reassess the need for continued anticoagulation and make a shared decision about discontinuation versus extension 1, 2

Critical Patient Education Points

• Emphasize strict adherence to twice-daily dosing—premature discontinuation or missed doses increase the risk of recurrent thrombosis 3

• If a dose is missed, take it as soon as remembered on the same day; do NOT double the next dose 3

• Instruct the patient to avoid NSAIDs, aspirin (unless specifically prescribed), and other antiplatelet agents that increase bleeding risk when combined with apixaban 3

• Warn about the risk of spinal/epidural hematoma if any neuraxial procedures (spinal tap, epidural injections) are planned—apixaban must be held for at least 48 hours beforehand 2, 3

• Provide clear instructions to notify providers before any surgical or dental procedures, as apixaban should be discontinued 24–48 hours prior depending on bleeding risk 3

Special Considerations for This Elderly Patient

• Verify that the 5 mg twice-daily dose is appropriate—the dose should be reduced to 2.5 mg twice daily only if she meets at least TWO of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 3

• Be vigilant for fall risk, as elderly patients on anticoagulation who fall have increased risk of intracranial hemorrhage; consider physical therapy referral and home safety evaluation 1

• Review all medications for drug interactions, particularly strong CYP3A4 and P-glycoprotein inhibitors (e.g., ketoconazole, clarithromycin) or inducers (e.g., rifampin, carbamazepine) that can alter apixaban levels 5, 3

When to Consider Extended Anticoagulation Beyond 3 Months

• Extended anticoagulation is NOT typically indicated for surgery-provoked VTE once the patient has recovered from surgery and is fully ambulatory 1, 4

• Reassess at 3 months for any new unprovoked risk factors (e.g., newly diagnosed cancer, antiphospholipid syndrome, recurrent VTE) that would warrant indefinite anticoagulation 1, 2

• If extended anticoagulation is deemed necessary after 6 months of treatment, reduce apixaban to 2.5 mg twice daily to minimize bleeding risk while maintaining efficacy for secondary prevention 2, 3

Red Flags Requiring Urgent Evaluation

• Major bleeding (requiring transfusion, involving critical sites such as intracranial or retroperitoneal, or causing hemodynamic instability) warrants immediate discontinuation of apixaban and emergency evaluation 3

• Symptoms of recurrent VTE while on therapeutic anticoagulation (breakthrough thrombosis) require urgent imaging and consideration of alternative diagnoses such as cancer-associated thrombophilia 5, 6

• New neurological symptoms (weakness, numbness, bowel/bladder dysfunction) in a patient who has undergone any spinal procedure require emergent evaluation for epidural hematoma 3

Common Pitfalls to Avoid

• Do NOT use prophylactic-dose apixaban (2.5 mg twice daily) for acute VTE treatment—this dose is only for extended secondary prevention after completing at least 6 months of therapeutic anticoagulation 2, 5

• Do NOT bridge with heparin or LMWH when transitioning from inpatient to outpatient apixaban therapy—unlike warfarin, apixaban does not require parenteral overlap 2, 3

• Do NOT routinely extend anticoagulation beyond 3 months for surgery-provoked VTE unless new risk factors emerge, as this increases bleeding risk without reducing recurrence in this low-risk population 1, 4

• Do NOT restart anticoagulation immediately after major bleeding—wait 24–72 hours until hemostasis is achieved, balancing the 5–7% case-fatality rate of recurrent VTE against bleeding mortality 5